Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer

In the treatment of advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitors have shown remarkable results. However, not all patients with NSCLC respond to this drug treatment or receive durable benefits. Thus, patient stratification and selection, as well as the identification of p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2020-11, Vol.12 (12), p.3574
Hauptverfasser:	Ghini, Veronica, Laera, Letizia, Fantechi, Beatrice, Monte, Francesca Del, Benelli, Matteo, McCartney, Amelia, Leonardo, Tenori, Luchinat, Claudio, Pozzessere, Daniele
Format:	Artikel
Sprache:	eng
Schlagworte:	Accuracy Biomarkers Cancer therapies Chemotherapy Clinical medicine Drug dosages Drug therapy Histology Immune checkpoint inhibitors Immunotherapy Ligands Lung cancer Magnetic resonance spectroscopy Medical prognosis Metabolomics NMR Non-small cell lung carcinoma Nuclear magnetic resonance Patients Principal components analysis Small cell lung carcinoma Statistical analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!